Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Basu · SciRah

Researcher profile · Semantic Scholar

B. Basu

Share profile

B. Basu — researcher profile on SciRah

h-index: 30
Works: 128
Citations: 3,071

Most-cited papers

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
D. Biasci, M. Smoragiewicz, C. Connell, Zhikai Wang +22 more
2020Proceedings of the National Academy of Sciences of the United States of America239 citations Open access
Semantic Scholar
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
H. Kocher, B. Basu, F. Froeling, D. Sarker +17 more
2020Nature Communications208 citations Open access
Semantic Scholar
Imaging breast cancer using hyperpolarized carbon-13 MRI
F. Gallagher, R. Woitek, M. McLean, A. Gill +40 more
2020Proceedings of the National Academy of Sciences of the United States of America178 citations Open access
Semantic Scholar
Quantifying normal human brain metabolism using hyperpolarized [1–13C]pyruvate and magnetic resonance imaging
J. Grist, M. McLean, F. Riemer, R. Schulte +22 more
2019NeuroImage167 citations Open access
Semantic Scholar
Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study
F. Walter, K. Mills, S. Mendonça, G. Abel +7 more
2016The Lancet Gastroenterology and Hepatology152 citations Open access
Semantic Scholar
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
D. Sarker, R. Plummer, T. Meyer, M. Sodergren +32 more
2020Clinical Cancer Research140 citations Open access
Semantic Scholar
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014
B. Basu, E. Dean, M. Puglisi, A. Greystoke +11 more
2015Clinical Cancer Research118 citations Open access
Semantic Scholar
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
N. Cook, B. Basu, Donna M. Smith, A. Gopinathan +15 more
2018British Journal of Cancer99 citations Open access
Semantic Scholar
Up-regulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and cancer patients
Ayumi Hashimoto, D. Sarker, V. Reebye, S. Jarvis +27 more
2021Clinical Cancer Research75 citations Open access
Semantic Scholar
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors
J. de Bono, L. Mina, Michael A. Gonzalez, N. Curtin +14 more
201372 citations Open access
Semantic Scholar
Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial
M. Alunni-Fabbroni, Kerstin Rönsch, T. Huber, C. Cyran +8 more
2019Journal of Translational Medicine63 citations Open access
Semantic Scholar
Surgical outcomes of gallbladder cancer: the OMEGA retrospective, multicentre, international cohort study
A. Balakrishnan, P. Barmpounakis, N. Demiris, A. Jah +17 more
2023EClinicalMedicine61 citations Open access
Semantic Scholar
A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer
A. Oza, U. Matulonis, Angeles Alvarez Secord, J. Nemunaitis +24 more
2019Clinical Cancer Research61 citations Open access
Semantic Scholar
Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
T. Yap, R. Kristeleit, V. Michalarea, S. Pettitt +32 more
2020Cancer Discovery60 citations Open access
Semantic Scholar
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.
C. Gomez-Roca, E. Yáñez, S. Im, Eduardo Castañón Álvarez +12 more
2021Journal of Clinical Oncology59 citations
Semantic Scholar
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Christina Guo, M. Chénard-Poirier, D. Roda, Maria de Miguel +22 more
2020The Lancet Oncology58 citations Open access
Semantic Scholar
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
Sergio Muñoz-Martínez, V. Sapena, A. Forner, J. Nault +81 more
2021JHEP Reports56 citations Open access
Semantic Scholar
Hyperpolarized 13C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer
R. Woitek, M. McLean, A. Gill, J. Grist +26 more
2020Radiology: Imaging Cancer49 citations Open access
Semantic Scholar
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience
E. Ghorani, Han H. Wong, C. Hewitt, J. Calder +2 more
2015Oncology48 citations
Semantic Scholar
Imaging Glioblastoma Metabolism by Using Hyperpolarized [1-13C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study
F. Zaccagna, M. McLean, J. Grist, J. Kaggie +29 more
2022Radiology: Imaging Cancer45 citations Open access
Semantic Scholar
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
J. Spicer, B. Basu, A. Montes, U. Banerji +28 more
2023Nature Communications40 citations Open access
Semantic Scholar
Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism.
F. Zaccagna, J. Grist, S. Deen, R. Woitek +4 more
2018British Journal of Radiology37 citations Open access
Semantic Scholar
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer
F. C. Martins, D. Couturier, I. de Santiago, Carolin M. Sauer +29 more
2022Nature Communications36 citations Open access
Semantic Scholar
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
B. Basu, M. G. Krebs, R. Sundar, R. H. Wilson +24 more
2018Annals of Oncology36 citations Open access
Semantic Scholar
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
O. Öcal, K. Schütte, J. Kupčinskas, E. Morkūnas +18 more
2021Journal of Cancer Research and Clinical Oncology32 citations Open access
Semantic Scholar
Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.
J. Harrington, T. Hernández-Guerrero, B. Basu
2017Clinics in oncology21 citations Open access
Semantic Scholar
Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer
J. Spicer, B. Basu, A. Montes, U. Banerji +31 more
2020Tumor Biology20 citations
Semantic Scholar
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.
H. Chung, Zarnie Lwin, C. Gomez-Roca, F. Longo +15 more
202119 citations
Semantic Scholar
Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
A. Azizi, A. V. Hadjinicolaou, Carla Gonçalves, A. Duckworth +1 more
2020Frontiers in Oncology19 citations Open access
Semantic Scholar
A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
T. R. Jeffry Evans, B. Basu, R. Hubner, Yuk-Ting Ma +16 more
2023Journal of Clinical Oncology18 citations
Semantic Scholar
The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma – a substudy of the SORAMIC trial
T. Labeur, Q. Hofsink, R. Takkenberg, O. V. van Delden +10 more
2020Acta oncologica17 citations Open access
Semantic Scholar
PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).
C. Gourley, J. Green, H. Gabra, I. Vergote +5 more
201617 citations
Semantic Scholar
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
P. Corrie, W. Qian, B. Basu, J. Valle +30 more
2020British Journal of Cancer16 citations Open access
Semantic Scholar
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
K. Sayal, I. Gounaris, B. Basu, S. Freeman +9 more
2015International Journal of Gynecologic Cancer15 citations Open access
Semantic Scholar
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Ruth Plummer, M. Sodergren, Rose Hodgson, Bríd M. Ryan +34 more
2025Cell Reports Medicine14 citations Open access
Semantic Scholar
Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI
Laura M. Lechermann, R. Manavaki, B. Attili, Doreen Lau +10 more
2020EJNMMI Research14 citations Open access
Semantic Scholar
Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma
A. Dayimu, Lorena Di Lisio, S. Anand, Isart Roca-Carreras +7 more
2023British Journal of Cancer13 citations Open access
Semantic Scholar
Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer
M. Feretis, Tengyao Wang, S. Iype, A. Duckworth +9 more
2017Pancreas13 citations Open access
Semantic Scholar
Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations
V. Michalarea, D. Roda, Y. Drew, S. Carreira +24 more
201613 citations
Semantic Scholar
An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.
U. Banerji, Á. Garces, V. Michalarea, R. Ruddle +16 more
201711 citations
Semantic Scholar
A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).
N. Cook, B. Basu, Donna M. Smith, A. Gopinathan +12 more
201410 citations
Semantic Scholar
Radiomic and Volumetric Measurements as Clinical Trial Endpoints—A Comprehensive Review
I. Funingana, P. Piyatissa, M. Reinius, C. McCague +2 more
2022Cancers9 citations Open access
Semantic Scholar
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
C. G. Leineweber, M. Rabehl, A. Pietzner, N. Rohwer +11 more
2023Frontiers in Pharmacology7 citations Open access
Semantic Scholar
Drug development and clinical trial design in pancreatico-biliary malignancies.
J. Harrington, L. Carter, B. Basu, N. Cook
2018Current Problems in Cancer7 citations Open access
Semantic Scholar
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.
U. Matulonis, A. Oza, A. Secord, L. Roman +16 more
20167 citations
Semantic Scholar
A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Susana Banerjee, V. Michalarea, J. Ang, A. I. Ingles Garces +25 more
2022Clinical Cancer Research6 citations Open access
Semantic Scholar
Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.
D. Sarker, E. Plummer, B. Basu, T. Meyer +7 more
20186 citations
Semantic Scholar
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).
C. Gourley, H. Gabra, I. Vergote, B. Basu +5 more
20156 citations
Semantic Scholar
STAR_PAC: A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab¬Paclitaxel for pancreatic cancer
H. Kocher, D. Propper, Sara Alabaf, K. Mousa +12 more
20165 citations
Semantic Scholar
PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC)
B. Basu, C. Gourley, H. Gabra, I. Vergote +5 more
20165 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. de Bono×8
Invite
J. de Bono — researcher profile on SciRah
U. Banerji×8
Invite
U. Banerji — researcher profile on SciRah
F. Gallagher×7
Invite
F. Gallagher — researcher profile on SciRah
D. Sarker×6
Invite
D. Sarker — researcher profile on SciRah

×6

Invite

R. Kristeleit — researcher profile on SciRah

Invite

M. Parmar — researcher profile on SciRah

Invite

A. Turner — researcher profile on SciRah

Invite

N. Tunariu — researcher profile on SciRah

Juanita Lopez×6

Invite

Juanita Lopez — researcher profile on SciRah

Invite

D. Jodrell — researcher profile on SciRah

Invite

R. Woitek — researcher profile on SciRah

Invite

M. McLean — researcher profile on SciRah